Treatment of Inflammatory Bowel Disease with Biologics
134 The use of anti-TNF agents has proved paramount in the remedy of Crohn’s disease, decreasing the overall need for surgery. H ...
135 (p ≤ 0.009) [ 7 ]. Subsequently infliximab received FDA approval for the treatment of moderate-to-severe UC and endorsement ...
136 determined [ 17 ]. Definition of perioperative treatment included exposure of ther- apy with infliximab, corticosteroids, or ...
137 Statistically adjusting for extent and severity of colitis, steroid dose, and use of immunomodulators, use of infliximab lea ...
138 Bearing in mind the higher risk of infectious complications in Crohn’s disease patients after anti-TNF exposure, similar con ...
139 References Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB, et al. Immunosuppressive therapy does not increase ...
140 Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complicatio ...
© Springer International Publishing AG 2018 141 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
142 may be a viable option. The concept of withdrawal of IBD therapies is not new. Prior to the introduction of anti- TNF- α the ...
143 Infusion Reactions Anti-TNF-α therapies are generally well tolerated with only a small proportion (4%) of patients experienc ...
14 4 Table 10.1 Studies on the withdrawal of anti-TNF- α therapies Authors Number of participants ( n) Study design Relapse rate ...
145 (continued) Molnar et al. [^43 ] 121 Prospective observational 45% (1 year) Previous biologic therapy Gender, concurrent ste ...
146 Ramos et al. [^79 ] 25 Retrospective 16% (1.6 ± 1 year) Not reported Not reported (% of IMM not reported) Waugh et al. [ ...
147 CD/UC Bortlik et al. [83] CD: 61UC: 17 Prospective observational (77% of CD and 59% of UC with concomitant IMM) CD: 18% (0.5 ...
148 Molander et al. [^67 ] CD,17; UC, 30 Prospective observational (83% with concomitant IMM) CD: 29% (1.1 year) Nil identified ...
149 Caviglia et al. [^85 ] CD: 29 Retrospective CD: 69% [median 1.3 (0.4–2.5) years] Not reported Not reported (100% CD and ...
150 Steenholdt et al. [ 57 ] CD: 53UC: 28 Retrospective 86% concomitant IMM (CD and UC) CD: 39% (1 year), 88% (10 years) CD: lon ...
151 Kennedy et al. [^45 ] 146 CD, 20 UC; 11 cohort totaling 746 patients (meta-analysis) Retrospective observational Observation ...
152 Predictive Factors for Relapse Multiple factors, both modifiable and non-modifiable, have been suggested to pre- dict risk o ...
153 Younger age at diagnosis was reported by two separate meta-analyses to be an adverse prognostic factor following anti-TNF-α ...
«
3
4
5
6
7
8
9
10
11
12
»
Free download pdf